Table 1.
Comparative characteristics of the E-FACED score’s construction and validation cohorts
| Variables | Construction cohort n=819 (%) | Validation cohort n=651 (%) |
|---|---|---|
| Age, years | 58.7 (17.6) | 48.2 (16) |
| Gender, % men | 356 (43.5) | 214 (32.9) |
| Body mass index, kg/m2 | 25.7 (4.7) | 22.4 (11.5) |
| Dyspnea (mMRC) | 1.53 (1.16) | 1.52 (1.05) |
| Smoking (pack-years) | 5.79 (18.1) | 4.81 (12.8) |
| Appearance of sputum, n (%) | ||
| Mucous | 199 (24.5) | 177 (27.2) |
| Mucopurulent | 145 (17.7) | 229 (35.2) |
| Purulent | 145 (17.7) | 124 (19) |
| Respiratory failure, n (%) | 83 (10.1) | 110 (16.9) |
| Number of affected lobes | 2.52 (1.2) | 3.37 (1.5) |
| Idiopathic bronchiectasis, n (%) | 310 (37.9) | 169 (26) |
| FEV1, % predicted | 68.9 (25.9) | 54.7 (22.1) |
| FVC, % predicted | 76.4 (20.3) | 67.2 (20.3) |
| Chronic colonization, n (%) | ||
| Pseudomonas aeruginosa | 260 (31.8) | 259 (39.8) |
| Haemophilus influenzae | 126 (15.4) | 67 (10.3) |
| Multiresistant microorganism | 40 (4.9) | 40 (6.14) |
| Isolation of Staphylococcus aureus, n (%) | 42 (5.1) | 49 (7.5) |
| Isolation of fungi, n (%) | 178 (21.7) | 39 (6) |
| Isolation of NTM, n (%) | 23 (2.8) | 8 (1.3) |
| Exacerbations (previous year)* | 2.52 (2.2) | 1.12 (1.4) |
| Hospitalizations (previous year) | 0.7 (1.2) | 0.4 (0.8) |
| Exacerbations/year (follow-up)* | – | 0.95 (0.9) |
| Hospitalization/year (follow-up) | – | 0.3 (0.5) |
| Chronic treatment, n (%) | ||
| Systemic antibiotics | 59 (7.2) | 46 (7.2) |
| Inhaled antibiotics | 146 (17.8) | 198 (30.5) |
| Macrolides | 110 (13.4) | 113 (17.3) |
| Oral corticoids | 39 (4.7) | 25 (3.8) |
| Death, n (%) | 154 (18.8) | 95 (14.6) |
Note:
*
The number of hospitalizations (severe exacerbations) are not included.
Abbreviations: mMRC, Modified Medical Research Council; NTM, non-tuberculous mycobacterium; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.